Syndax Pharmaceuticals (SNDX) Net Equity Issued and Repurchased (2015 - 2023)
Syndax Pharmaceuticals (SNDX) posted quarterly Net Equity Issued and Repurchased of $216.0 million for Q4 2023, up 33.31% year-over-year from $162.0 million in Q4 2022, and up 33.31% quarter-over-quarter from $162.0 million in Q4 2022.
Syndax Pharmaceuticals (SNDX) Net Equity Issued and Repurchased (2015 - 2023) Analysis & Trends
Syndax Pharmaceuticals' Net Equity Issued and Repurchased history runs 8 years deep, the most recent figure standing at $216.0 million for Q4 2023.
- In Q4 2023, Net Equity Issued and Repurchased rose 33.31% year-over-year to $216.0 million; the TTM figure through Dec 2023 stood at $378.0 million (up 55.41% YoY), while the FY2023 annual figure was $216.0 million, up 1011.74% from the prior year.
- Net Equity Issued and Repurchased for Q4 2023 stood at $216.0 million, up from $162.0 million in the prior quarter.
- The five-year high for Net Equity Issued and Repurchased was $216.0 million in Q4 2023, with the low at -$69.9 million in Q2 2021.
- The 5-year median for Net Equity Issued and Repurchased is $54.9 million (2020), against an average of $59.7 million.
- The sharpest annual moves came in 2019 and 2020: Net Equity Issued and Repurchased sank 538.17% in 2019, then soared 359570.0% in 2020.
- Syndax Pharmaceuticals' Net Equity Issued and Repurchased stood at -$26.5 million in 2019, then jumped by 608.49% to $135.0 million in 2020, then sank by 39.85% to $81.2 million in 2021, then jumped by 99.51% to $162.0 million in 2022, then surged by 33.31% to $216.0 million in 2023.
- Business Quant data shows SNDX's Net Equity Issued and Repurchased at $216.0 million in Q4 2023, $162.0 million in Q4 2022, and $81.2 million in Q4 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Equity Issued and Repurchased (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 49.20 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 141.90 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Syndax Pharmaceuticals | 1.77 Bn | 1.22 Bn | 60.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 215.96 Mn |
| Dec 31, 2023 | 215.96 Mn |
| Dec 31, 2022 | 162.00 Mn |
| Dec 31, 2022 | 162.00 Mn |
| Dec 31, 2021 | 81.20 Mn |
| Dec 31, 2021 | 81.20 Mn |
| Jun 30, 2021 | -69.87 Mn |
| Jun 30, 2021 | -69.87 Mn |
| Mar 31, 2021 | 75.00 Mn |
| Mar 31, 2021 | 75.00 Mn |
| Dec 31, 2020 | 135.00 Mn |
| Dec 31, 2020 | 135.00 Mn |
| Sep 30, 2020 | -33,000.00 |
| Sep 30, 2020 | -33,000.00 |
| Jun 30, 2020 | 107.90 Mn |
| Jun 30, 2020 | 107.90 Mn |
| Mar 31, 2020 | 34.87 Mn |
| Mar 31, 2020 | 34.87 Mn |
| Dec 31, 2019 | -26.55 Mn |
| Dec 31, 2019 | -26.55 Mn |